2,239 press releases in English indexed under biotech & pharma.
The Bio Decontamination Market is expanding as healthcare facilities, pharmaceutical manufacturers, biotechnology companies, and research laboratories increasingly prioritize contamination control and sterile operating environments. Bio decontamination involves the use of specialized technologies and chemical agents to eliminate or reduce biological ... Read more
Poster presentation to highlight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumors BOSTON, Oct. 19, 2026 -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the...
NEWTOWN SQUARE, Pa., Oct. 19, 2026 -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the publication of FURTHER Phase 1b (FURMO-002; NCT05364073) results of firmonertinib in Cancer Cell, highlighting the preclinical and clinical findings supporting its potential, if approved, as the first oral, chemotherapy-free targeted therapy for treatment-naïve patients with advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC).
Vancouver, British Columbia--(October 19, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of Physical AI systems, including Self-Driving Laboratories ("SDL"), enabling technologies, and services for the global pharmaceutical and high-value chemical industries, today announced that it has been chosen to join the Canadian business delegation to BIOPLUS-INTERPHEX Korea ("BIX"), taking place October 27-30,...
On October 19, 2026, Ambassador Han Jing paid a courtesy call on Hon. Prof. Roma Chilengi, Minister of Health of Zambia. Ambassador Han congratulated Prof. Chilengi on his appointment and said that, under the strategic guidance of the two Heads of State, China-Zambia comprehensive strategic and cooperative partnership has continued to grow. China attaches great importance to health cooperation and stands ready to strengthen communication and coordination with the Zambian side, deepen cooperation in medical team dispatches, pharmaceutical supplies assistance, health infrastructure development, and continue to improve the health and well-being of the Zambian people. Prof. Chilengi thanked China for its long-standing support for Zambia’s health sector, noting that Zambia values its traditional friendship with China and looks forward to further deepening bilateral cooperation in health and achieving more tangible outcomes. Distributed by APO Group on behalf of Embassy of the People's Republic of China in the Republic of Zambia.
— New Studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies — Cesalatamig is Also Being Evaluated in Ongoing Phase 2 Studies in the United States and in China ROCKVILLE, Md. , Oct. 19, 2026 -- OncoC4 Inc., a late clinical-stage...
The Investment underscores ZAP's momentum in neuro-oncology and emerging neuropsychiatric applications SAN CARLOS, Calif., October 19, 2026--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced it has secured $36 million in financing led by Catalio Capital
- Clearance enables initiation of SHIELD-AL, a pivotal study in newly diagnosed patients with lambda AL amyloidosis - Investigational oral light chain stabilizer to be evaluated as an add-on to standard-of-care plasma cell-directed therapy SAN DIEGO, Oct. 19, 2026 -- Protego...
PASADENA, Calif., October 19, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1
—BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan— BRIDGEWATER, N.J., Oct. 19, 2026 -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical...
WATERTOWN, Mass., Oct. 19, 2026 -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP). The trial met all its primary and secondary endpoints.
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM